India's first mRNA Covid-19 vaccine gets nod to start phase 1 trials


 

The Central Drugs Standard Control Organisation on Wednesday permitted Pune-based Gennova Biopharmaceuticals to conduct Phase 1/2 clinical trials, along with animal toxicity data, for its mRNA Covid-19 vaccine candidate.

It is India's first messenger RNA (mRNA) Covid vaccine candidate. Globally, US-based pharma giant Pfizer Inc has developed its mRNA vaccine.

The permission was granted after the Subject expert Committee (SEC) for vaccines recommended for grant of permission in a review meeting on Wednesday, a document carrying the recommendations and accessed by IANS showed.

"After detailed deliberation, the committee recommended for grant of permission to conduct Phase 1/2 clinical trial subject to the condition that the interim results of Phase 1 study shall be submitted to the committee before proceeding to the next phase," the document read. Read More

 

Comments

Popular posts from this blog

Instagram adds group video call, new camera effects to app: How they work

3 Investment Strategies for Financial Independence!

G7 pledges 870 mn Covid vaccine doses, half to be delivered by 2021-end